The Radoff-JEC Group Issues Open Letter to Seer Inc.'s Board of Directors Regarding the Immediate Need for Significant Change
Leading Scientists Demonstrate How Seer's Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026
Nature Genetics Study Validates Seer's Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers
RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics 2025
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline
